Page 116 - 南京医科大学自然版
P. 116
第45卷第7期
·1014 · 南 京 医 科 大 学 学 报 2025年7月
Drugs,2021,35(2):215-231 [21]LEVIN E D,CONNERS C K,SILVA D,et al. Transder⁃
[11]卢望丁,朱慧勇,黄 英,等. 改良型透皮给药系统的开发 mal nicotine effects on attention[J]. Psychopharmacology
要点阐述[J]. 中国医药工业杂志,2022,53(5):621-628 (Berl),1998,140(2):135-141
LU W D,ZHU H Y,HUANG Y,et al. Key points in the [22]段继雯. 海绵骨针用于胰岛素经皮给药的研究[D]. 厦
development of modified transdermal drug delivery sys⁃ 门:厦门大学,2020
tems[J]. Chinese Journal of Pharmaceuticals,2022,53 DUAN J W. Study on the use of sponge spicules for trans⁃
(5):621-628 dermal insulin delivery[D]. Xiamen:Xiamen University,
[12]曾春香,严俊珍,徐佳兰,等. 水合氯醛透皮贴剂的药物 2020
动力学及生物利用度研究[J]. 中国现代药物应用, [23]HONG Y C,YU H J,WANG L,et al. Transdermal insulin
2017,11(6):189-191 delivery and microneedles⁃based minimally invasive de⁃
ZENG C X,YAN J Z,XU J L,et al. Pharmacokinetics livery systems[J]. Curr Pharm Des,2022,28(39):3175-
and bioavailability study of chloral hydrate transdermal 3193
patches[J]. Chinese Journal of Modern Drug Application, [24]ZHAO J,XU G Y,YAO X,et al. Microneedle⁃based insu⁃
2017,11(6):189-191 lin transdermal delivery system:current status and trans⁃
[13]徐 敏. α⁃细辛醚经皮给药贴剂的研究[D]. 杭州:浙 lation challenges[J]. Drug Deliv Transl Res,2022,12
江大学,2003 (10):2403-2427
XU M. Study on α ⁃ asarone transdermal patches[D]. [25]SUGUMAR V,HAYYAN M,MADHAVAN P,et al. Cur⁃
Hangzhou:Zhejiang University,2003 rent development of chemical penetration enhancers for
[14]NIHADHA P M,CHUGH A,KAUR A,et al. Transdermal transdermal insulin delivery[J]. Biomedicines,2023,11
fentanyl patch versus standard analgesia in postoperative (3):664
oral submucous fibrosis patients:a triple blinded,ran⁃ [26]ZHAI H J,ZHANG C,OU H L,et al. Transdermal deliv⁃
domised control trial[J]. Br J Oral Maxillofac Surg,2022, ery of heparin using low⁃frequency sonophoresis in combi⁃
60(9):1246-1253 nation with sponge spicules for venous thrombosis treat⁃
[15]KUMAR R,SINHA V R,DAHIYA L,et al. Preclinical in⁃ ment[J]. Biomater Sci,2021,9(16):5612-5625
vestigation of transdermal route for enhanced bio⁃perfor⁃ [27]邓汉沣,王亚丽,冯震震,等. 帕金森病非运动症状便秘
mance of duloxetine HCl[J]. AAPS PharmSciTech,2023, 机制及临床研究进展[J]. 辽宁中医药大学学报,2024,
24(6):154 26(8):74-78
[16]HAJEK P,PRZULJ D,PESOLA F,et al. Electronic ciga⁃ DENG H F,WANG Y L,FENG Z Z,et al. Mechanisms
rettes versus nicotine patches for smoking cessation in and clinical research progress on constipation in non⁃mo⁃
pregnancy:a randomized controlled trial[J]. Nat Med, tor symptoms of Parkinson’s disease[J]. Journal of Liaon⁃
2022,28(5):958-964 ing University of Traditional Chinese Medicine,2024,26
[17]CROUSER E D,SMITH R M,CULVER D A,et al. A pi⁃ (8):74-78
lot randomized trial of transdermal nicotine for pulmonary [28]钱 青,王庆广,李现文. 血管紧张素及其转化酶与帕
sarcoidosis[J]. Chest,2021,160(4):1340-1349 金森病患者认知障碍与运动障碍的关系[J]. 南京医科
[18]LEE K,CHEATHAM C C,MACK G W. Cold⁃induced va⁃ 大学学报(自然科学版),2025,45(2):218-226
sodilation in abstinent smokers with and without a 12 ⁃ QIAN Q,WANG Q G,LI X W. Correlation between angio⁃
hour nicotine patch[J]. Microcirculation,2021,28(6): tensin with its converting enzyme and disorders of cogni⁃
e12701 tion and motor in patients with Parkinson’s disease[J].
[19]YAMMINE L,VERRICO C D,VERSACE F,et al. Exena⁃ Journal of Nanjing Medical University(Natural Scienc⁃
tide as an adjunct to nicotine patch for smoking cessation es),2025,45(2):218-226
and prevention of postcessation weight gain among treat⁃ [29]张亚茹,张 一,郁金泰. 2022年阿尔茨海默病重要研
ment ⁃ seeking smokers with pre ⁃ diabetes and/or over⁃ 究进展[J]. 南京医科大学学报(自然科学版),2023,43
weight:study protocol for a randomised,placebo ⁃ con⁃ (4):563-568
trolled clinical trial[J]. BMJ Open,2023,13(6): ZHANG Y R,ZHANG Y,YU J T. Research advances of
e072707 Alzheimer’s disease in 2022[J]. Journal of Nanjing Medi⁃
[20]BAKER T B,PIPER M E,SMITH S S,et al. Effects of cal University(Natural Sciences),2023,43(4):563-568
combined varenicline with nicotine patch and of extended [30]王诗铫,黄志航,蒋 腾. TREM2在阿尔茨海默病中的
treatment duration on smoking cessation:a randomized 研究进展[J]. 南京医科大学学报(自然科学版),2024,
clinical trial[J]. JAMA,2021,326(15):1485-1493 44(5):698-704

